



your
partner
that
cares

VALUE ADDED MEDICINES

Oromucosal Delivery
Complex Steriles
OSD Fixed-Dose Combinations

 **bluepharma**

Oromucosal delivery

BlueOS® and **BluEase™** are innovative and versatile platforms based on proprietary technologies for the delivery of drug substances through the oral mucosa and gastrointestinal tract.

These patient centric technologies enable both the incorporation of New Chemical Entities and the repurposing of known drugs, including off patent molecules.

Crossing boundaries
towards **patients'** needs,
prescribers' confidence
and **payers'** outcomes.



CONVENIENCE

Allowing patients and caregivers to succeed:

- Patients with dysphagia and difficulties to swallow, - such as pediatrics and geriatrics.
- Emergency situations and non-collaborative patients.
- On-the-go solution.



ADHERENCE AND SAFETY

Giving confidence to prescribers.

- Improved convenience resulting in improved adherence.
- Potential to be less invasive as compared to existing solutions.
- Potential for improved bioavailability and fast onset of actio.



SAVINGS

Improved adherence allows for better outcomes and less visits to the hospital, representing savings to payers.

Potential Applications

- Multiple Sclerosis
- Epilepsy
- Parkinson's Disease
- Dementia
- Migraine
- Opioid Overdose
- Alcohol Use Disorder



Oral Thin Films
BlueOS®




Buccal Sprays
BluEase™

Oral Thin Films BlueOS®

Buccal Sprays BluEase™

Oral Dispersible Tablet



OSD Fixed-Dose Combinations

Development of advanced formulations that aim the modulation of the release profile, overcome barriers such as incompatibilities between molecules and increase of the stability, including **multi-layer tablets**, **micro tablets**, **capsule-in-capsule** and **Hot Mel Extrusion** technologies.

Blue073	Candesartan	<ul style="list-style-type: none"> • Multi-layer technology • Cardiovascular Therapeutic Field • Available
	Atorvastatin	
	Amlodipine	
Blue074	Ramipril	
	Atorvastatin	
	Amlodipine	

MULTILAYER TECHNOLOGY

Get more out of a single tablet




HOT MELT EXTRUSION
Overcoming formulation barriers

Complex Steriles

Complex Steriles offer unique advantages and solve major challenges of conventional oral or parenteral drug delivery systems.

Lipid nanoparticles (LNP)

Bluepharma has more than 25 years of accumulated experience in **lipid-based formulations** (unilamellar liposomes, multivesicular liposomes, targeted and pH sensitive liposomes)




INDICATION	VALUE PROPOSITION	TYPE OF FORMULATION	Technical POC	Formulation Development	Non-clinical POC	Clinical POC	Scale-up
Oncology Mesothelioma	<ul style="list-style-type: none"> Improved SAFETY and EFFICACY IP granted in major markets WW Orphan Drug Designation granted by FDA and EMA (Mesothelioma) 	Liposomal				ongoing	
Rheumatoid Arthritis	<ul style="list-style-type: none"> Improved SAFETY, reducing adverse events Dosing Convenience by decreasing the number of administrations 	Liposomal					ongoing

Polymer-based microparticles

Bluepharma is developing an **innovative LAI technology** that takes advantage of a hybrid system comprising an in-situ forming hydrogel with embedded microparticles:

- High loading capacity.
- Ability to encapsulate more than one drug.
- Fine-tuning of the drug release profile.
- Minimal or inexistent burst release.



Create **value** through **Innovation**. How? Contact us!

For business inquiries:

business@bluepharma.pt

Coimbra · PORTUGAL

Tel. +351 239 800 300

www.bluepharmagroup.com



scan me
Product Portfolio



Bluepharma's facilities are **EU-GMP certified** and approved by:

- US FDA (2009, 2012, 2014, 2016, 2019)
- SFDA (Kingdom of Saudi Arabia)
- ANVISA (Brazil)
- MFDS (Republic of Korea)
- Minpromtorg (Russian Federation)
- MOH Libya
- TMMDA (Turkey)

We are registered in **Iraq, Taiwan, Jordan, UAE, Kurdistan and Vietnam.**